WCG Data-Driven Site Identification Delivers the Best-Fit Sites, Optimizes Enrollment, Leading to Significant Cost Savings

By applying proprietary intelligence to the site identification process, WCG Predict™ can reliably increase study enrollment performance and provide improved predictability for timeline planning. In the actual trial analyzed below, by selecting only the top-performing sites, WCG Predict™ would have reduced enrollment time by six months and saved the sponsor $750,000 in fully loaded costs.

reduced enrollment time by
6 months

saved the sponsor
$750,000
in fully loaded costs.

WCG Predict™ can put this intelligence to work for you, helping select sites with the best recruitment potential, enhance ROI and get your study to key milestones
more reliably and faster.

Biopharmaceutical companies need to identify the sites that optimize enrollment, ensure data quality and maximize ROI. But how do you find those sites? And how do you make the most of your study start-up budget?

The answer: You need access to cutting-edge, real-time data on sites, and you need expert insights to interpret that data. WCG Predict™-part of the WCG Total Feasibility™ suite-precisely matches a study's therapeutic approach and protocol against historical performance data from thousands of global clinical studies, investigators and institutions. These data are housed within the WCG Knowledge Base™, which contains data on over 95% of industry-sponsored research. These proprietary data and insights allow us to give each client a specific, hand-tailored list of those sites most likely to be higher enrollers for their upcoming study. More importantly, it also provides better insights for more accurate site optimization, competitive intelligence for better study placement, and an ability to tap the experience of our clinical trialists who can help your team navigate the treacherous waters of accurate study planning.

The result: Faster time to your next key decision point, improved ROI and better insight to study planning timelines and milestones.

wcg™

609.945.0101 / **www.wcgclinical.com**

The Analysis

To assess how WCG Predict™ could enhance study enrollment performance, we conducted a retrospective analysis of a completed trial for type 2 diabetes. This trial required 150 patients and was conducted in the U.S. and Canada. Utilizing 44 sites, the actual study enrollment was 0.15 patients per site per month (PPSPM). It took 19 months to complete.

Actual Enrollment in Months: 19

High Performing Sites in Months: 13

6 months saved



Using WCG Knowledge Base™ data, we conducted the retrospective analysis by identifying the top two quartiles of sites who had been successful in similar studies. Using the top 29 sites from this analysis, enrollment was projected to be 0.24 PPSPM, shortening enrollment time by over 30% from 19 months to 13 months.

This optimized theoretical model shortened enrollment by six months (>30%), reduced the number of sites by 15 (34%) and saved the sponsor at least $750,000 in fully loaded costs.

What Was Different?

As noted, we achieved this by identifying sites ranked in the top quartiles, based on data from WCG's Knowledge Base™. In the actual study site cohort, more than 60% of the sites ranked in the bottom two quartiles, signifying the set of sites who are considered to be low-performing based on historical data, when compared to their peers.

Before WCG Predict™



After WCG Predict™



Use of WCG Predict™ could have reduced the total number of sites from 44 to 29 (a 34% reduction). Using a conservative estimate of $50,000[ii] per site, this would have saved the sponsor $750,000-a figure that doesn't include the savings accrued by a shorter enrollment period.

Optimize Site Identification with Proprietary Data

WCG Predict™ has more information about sites' enrollment performance than any other site identification tool. The WCG Knowledge Base™ includes data on 95% of all industry-sponsored research, enrollment performance on 85% of all FDA-regulated investigators, and demographic and performance metrics for more than 140,000 investigators worldwide. Importantly, this is regulatory-verifiable performance information for investigational sites.

Using these data, WCG's Knowledge Base™ runs a series of proprietary algorithms that yield a sub-set of investigators representing the site profile that was proactively identified for the study. The application force-ranks the sub-set of identified sites in order of predictive performance: Quartile 1, 2, 3 or 4. **The chart on the next page shows the value of this model and WCG's approach to site selection.**

In most cases, WCG can match you to the right sites within

10 business days.

WCG Predict™ can put this intelligence to work for you, helping select sites with the best recruitment potential, enhance ROI and get your study to key milestones more reliably and faster.

Contact us at info@wcgclinical.com to learn more.

WCG Total Feasibility™ is an end-to-end service that brings knowledge, speed, transparency and control to the site feasibility process so that sponsors and CROs have the time and information to make the best site selection decisions. It uses the leading data intelligence source, WCG Predict™, to provide predictive and actionable intelligence so you can make the right investigator choices. WCG Predict™ is complemented by our electronic feasibility system that collates and organizes investigator responses in real time, making them available instantaneously.

[i] The WCG Knowledge Base™ is the data collection and decision platform designed to provide real-time data and insights into global clinical trials. Gain actionable insights to advance current and planned studies with the WCG Knowledge Base™.

[ii] Sourced from Cutting Edge Information Clinical Operations Benchmarking Costs (2011).

wcg™

609.945.0101 / **www.wcgclinical.com**